A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Inclusion Criteria

• •1. Eastern Cooperative Oncology Group (ECOG) performance status of \<=2.
• •2. Has received previous myeloma-specific therapy.
• •3. In the Combination Cohort (TAK-079-PomDex) only must be able to take concurrent prophylactic anticoagulation per standard clinical practice as directed by the investigator and the Pomalyst product information.
• •4. Documentation of RRMM as defined by the International Myeloma Working Group (IMWG) criteria.
• •5. For Participants with MM, measurable disease defined as one of the following:
• •* Serum M-protein \>=0.5 g/dL (\>=5 gram per liter \[g/L\]).
• •* Urine M-protein \>=200 mg/24 hours.
• •* In participants without measurable M-protein in serum protein electrophoresis (SPEP) or urine protein electrophoresis (UPEP), a serum FLC assay result with involved FLC level \>=10 mg/dL (\>=100 milligram per liter \[mg/L\]), provided serum FLC ratio is abnormal.
• •6. Prior therapy should meet all the following criteria:
• •Participants in the dose Escalation Cohort (escalation phase) and participants in the dose Confirmation Cohort;
• •* Should be previously treated with at least a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and a steroid. Note: Participants who have had a previous autologous stem cell transplant will have additionally been exposed to an alkylating agent; however, participant who have not had a previous autologous stem cell transplant may not have been exposed to an alkylating agent per standard practice.
• •* Should be refractory or intolerant to at least 1 PI and at least 1 IMiD.
• •* Should either have received \>= 3 prior lines of therapy or should have received at least 2 prior lines of therapy if one of those lines included a combination of PI and IMiD.
• •* In phase 1, previous exposure to an anti-CD38 agent, as a single agent or in combination, is allowed but is not required. (Participants in the dose Escalation Cohort).
• •* In phase 1 dose Confirmation Cohort, cohorts of participants that are refractory at any time to at least 1 anti-CD38 agent or who are anti-CD38 naïve will be enrolled.
• •Participants in the Combination Cohort (TAK-079 added to PomDex cohort only):
• •* Have undergone prior therapy with \>=2 prior anti-myeloma therapies (line of therapy defined below).
• •* Has either relapsed or relapsed and refractory disease. Should have progressed on or within 60 days of completing the last anti-myeloma therapy (refractory defined below).
• •7. In the phase 2a portion of the study, up to 2 cohorts of participants with RRMM may be enrolled: 1 that is refractory to at least 1 anti-CD38 monoclonal antibody (mAb) therapy at any time during treatment and 1 that is naïve to daratumumab.
• •Note:
• •o Refractory is defined as at least a 25% increase in M-protein (response of stable disease during prior therapy) or PD during treatment or within 60 days after last dose of prior therapy.